Clinical trials sponsored by industry and other private organizations

被引:0
作者
Cortelli, Sheila Cavalca [1 ]
Costa, Fernando Oliveira [2 ]
Lousana, Greyce [3 ]
Ribeiro Quintairos, Paulo Cesar [1 ]
Francisconi-dos-Rios, Luciana Favaro [4 ]
Cortelli, Jose Roberto [1 ]
机构
[1] Univ Taubate Unitau, Off Grad Studies & Sci Affairs, Taubate, SP, Brazil
[2] Univ Fed Minas Gerais UFMG, Sch Dent, Periodont Dept, Belo Horizonte, MG, Brazil
[3] Invitare Clin Res, Sao Paulo, SP, Brazil
[4] Univ Sao Paulo, Sch Dent, Dept Operat Dent, Sao Paulo, SP, Brazil
来源
BRAZILIAN ORAL RESEARCH | 2020年 / 34卷
关键词
Provider-Sponsored Organizations; Industry; Private Sector; Clinical Trial; Support of Research;
D O I
10.1590/1807-3107bor-2020.vol34.0077
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
The present manuscript discussed some relevant aspects related to private sponsored clinical trials in dentistry. For decades, the academy has been the major responsible for research in Brazil. Distant from the trade sector, academic research has not always provided clear benefits to society. A key aspect of making benefits clearer is the process of scientific knowledge transference to decision-makers, which is, in fact, the ground of evidence-based dentistry. Although private sponsoring of clinical research seems to be part of the research progress of the business rates, investment in Brazil is lower than those observed in other countries. It is particularly important to understand that instead of creating its own rules, dentistry imported the high-quality standards originally designed for pharmaceutical studies. Therefore, it is critical to understand the original rules and how dental items are classified by regulatory agencies. In fact, knowledge about international and local regulation is a basic assumption in industry- sponsored research. Despite globalization, the identification of industry-sponsored studies through open access databases is still very hard and time-demanding. A common concern when conducting industry- sponsored trials is study biases. Fortunately, many relevant organizations, academic and industry groups, have been working seriously against that. Finally, for less experienced researchers, many aspects related to industry- sponsored studies - such as confidentiality, authorship, budget - are deeply discussed until a final version of the trial agreement can be written and signed, protecting all sides. In short, the scenario should be improved, but it already represents a nice opportunity for dental research.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Pharmacy Workload in Clinical Trial Management: A Preliminary Complexity Assessment Tool for Sponsored Oncology and Haematology Trials
    Gasperoni, Lorenzo
    Masini, Carla
    Toscano, Giada
    Cafaro, Alessandro
    Zani, Chiara
    Andriano, Cristina
    Silimbani, Paolo
    Donati, Caterina
    Bortolin, Giorgia
    Cecco, Sara
    CURRENT ONCOLOGY, 2024, 31 (05) : 2867 - 2873
  • [22] Practicing research ethics: Private-sector physicians & pharmaceutical clinical trials
    Fisher, Jill A.
    SOCIAL SCIENCE & MEDICINE, 2008, 66 (12) : 2495 - 2505
  • [23] Developing a clinical trial governance framework for pharmaceutical industry-funded clinical trials
    Nair, Satish Chandrasekhar
    AlGhafli, Shamsa
    AlJaberi, Ayesha
    ACCOUNTABILITY IN RESEARCH-POLICIES AND QUALITY ASSURANCE, 2018, 25 (7-8): : 373 - 386
  • [24] Characteristics of contemporary atrial fibrillation clinical trials and their association with industry sponsorship
    Lan, Roy H.
    Paranjpe, Ishan
    Saeed, Mohammad
    V. Perez, Marco
    HEART RHYTHM, 2024, 21 (09) : 1517 - 1523
  • [25] Industry Collaboration and Primary Guest Authorship of High-Impact Clinical Trials
    Nitin Roper
    Deborah Korenstein
    Journal of General Internal Medicine, 2016, 31 : 12 - 12
  • [26] Five-step authorship framework to improve transparency in disclosing contributors to industry-sponsored clinical trial publications
    Marusic, Ana
    Hren, Darko
    Mansi, Bernadette
    Lineberry, Neil
    Bhattacharya, Ananya
    Garrity, Maureen
    Clark, Juli
    Gesell, Thomas
    Glasser, Susan
    Gonzalez, John
    Hustad, Carolyn
    Lannon, Mary-Margaret
    Mooney, LaVerne A.
    Pena, Teresa
    BMC MEDICINE, 2014, 12
  • [27] Five-step authorship framework to improve transparency in disclosing contributors to industry-sponsored clinical trial publications
    Ana Maruš.ić
    Darko Hren
    Bernadette Mansi
    Neil Lineberry
    Ananya Bhattacharya
    Maureen Garrity
    Juli Clark
    Thomas Gesell
    Susan Glasser
    John Gonzalez
    Carolyn Hustad
    Mary-Margaret Lannon
    LaVerne A Mooney
    Teresa Peña
    BMC Medicine, 12
  • [28] Current practices in author agreements for industry-sponsored publications
    Schweers, Sonia A.
    Fisher, Clair
    Nguyen-Cao, Tam
    Bhatia, Radhika
    Marchington, Jackie
    Goldman, Keith H.
    Stahl, Shannon
    Kshatriya, Bhakti
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 : S16 - S16
  • [29] Climate footprint of industry-sponsored clinical research: an analysis of a phase-1 randomised clinical study and discussion of opportunities to reduce its impact
    Laroche, Jason Keith
    Alvarenga, Rodrigo
    Collins, Michael
    Costelloe, Thomas
    De Soete, Wouter
    Faludi, Jeremy
    Rens, Kristel
    BMJ OPEN, 2024, 14 (01):
  • [30] Establishment of Advanced Regulatory Innovation for Clinical Trials Transformation (ARICTT): a multi-stakeholder public-private partnership-based organization to accelerate the transformation of clinical trials
    Chung, Woo Kyung
    Huh, Ki Young
    Park, Jiyeon
    Oh, Jaeseong
    Yu, Kyung-Sang
    TRANSLATIONAL AND CLINICAL PHARMACOLOGY, 2024, 32 (01) : 30 - 40